Latest research on Raloxifene

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. [PubChem]

Raloxifene indications

For example, the antiestrogens Raloxifene and Tamoxifen are equally effective in preventing the growth of estrogen-dependent breast cancers without inhibiting bone responses but Raloxifene has much reduced estrogenic effects in uteri, making it preferable in treating breast cancers [1,4]. [source, 2015]
With regard to the bone quality improvement effects of SERMs, Raloxifene has been reported to decrease homocysteine levels and to decrease pentosidine cross-linking [12, 14]. [source, 2015]
With respect to lipid metabolism, Raloxifene and bazedoxifene have previously been reported to decrease LDL-C, but no consensus has been achieved about the effects on HDL-C or TG [25, 26]. [source, 2015]
In a study conducted in New Delhi to determine the effect of Raloxifene on bone loss by quantitative ultrasound and bone turnover markers (bone-specific alkaline phosphatase) in postmenopausal women with osteopenia/osteoporosis over a 6-month period, authors found that there was no significant improvement in BMD over the 6-month treatment period. [source, 2015]
However, Raloxifene had a favorable effect on bone turnover as judged by a significant fall in serum bone-specific alkaline phosphatase.74 [source, 2015]
In the present study, we conducted a prospective randomized clinical phase IIA trial to investigate the effects of SERMs (toremifene and Raloxifene) when added to ADT in treatment-naïve bone metastatic PC. [source, 2015]
Raloxifene, which acts as an ER agonist in the bone tissue [26], has been developed for the treatment of osteoporosis in women [27] and showed some tumor-inhibitory effects in CRPC in a pilot study [13]. [source, 2015]
Raloxifene, a SERM with a proven estrogen agonist action on bone with estrogen antagonist actions on other tissues, was not effective in inducing epiphyseal closure in an aromatase-deficient man after 24 months of treatment [134]. [source, 2015]
Raloxifene, a second-generation selective estrogen receptor modulator, is approved for use in the treatment of osteoporosis in postmenopausal women and for breast cancer in women and can have beneficial effects on brain function including increased cortical plasticity. [source, 2015]
On the basis of our own findings that the action of estrogen receptors in brain may be blunted in males and females with schizophrenia and the previous studies showing beneficial effects of adjunctive Raloxifene treatment on cognition in older men and women, we predicted that adjunctive Raloxifene treatment at a daily dosage of 120 mg would improve cognitive deficits, particularly in the domain of verbal memory, and reduce symptoms in both men and women with schizophrenia. [source, 2015]